Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2015
Same author

Mitral valve prolapse and glaucoma: a 'floppy' perception?

Heart (British Cardiac Society)·2015
Same author

Prioritizing causal disease genes using unbiased genomic features.

Genome biology·2015
Same author

Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C.

European journal of preventive cardiology·2015
Same author

Inflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham Heart Study.

Neurology·2015
Same author

Endogenous carbon monoxide and cardiometabolic risk: can measuring exhaled carbon monoxide be used to refine cardiometabolic risk assessment?

Future cardiology·2015
Same journal

Disruptions of the diffusion tensor image analysis along the perivascular space index and dynamic functional connectivity across the Alzheimer's disease spectrum: Implications for cognitive impairment.

Journal of Alzheimer's disease : JAD·2026
Same journal

HbA1c trajectories after SGLT2 inhibitor initiation and the risk of dementia.

Journal of Alzheimer's disease : JAD·2026
Same journal

The role of organochlorine pesticides as environmental factors in Alzheimer's disease in human studies: A systematic review and meta-analysis.

Journal of Alzheimer's disease : JAD·2026
Same journal

Plasma profiling of B lymphocyte-associated cytokines in Alzheimer's disease.

Journal of Alzheimer's disease : JAD·2026
Same journal

Diluting the signal: Class-level pooling and the ecological fallacy in meta-analyses of anti-amyloid monoclonal antibodies.

Journal of Alzheimer's disease : JAD·2026
Same journal

Gut microbiota alterations in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis.

Journal of Alzheimer's disease : JAD·2026
See all related articles

Related Experiment Videos

Thyroid function and Alzheimer's disease.

Zaldy S Tan1, Ramachandran S Vasan

  • 1Division of Aging, Brigham and Women's Hospital, Boston, MA 02160, USA. ztan@hms.harvard.edu

Journal of Alzheimer'S Disease : JAD
|March 12, 2009
PubMed
Summary
This summary is machine-generated.

Thyroid dysfunction may increase Alzheimer's disease risk. Understanding thyroid hormone's role in brain function and dementia is crucial for future research and potential interventions.

Related Experiment Videos

Area of Science:

  • Neuroendocrinology
  • Neurology
  • Gerontology

Background:

  • Thyroid dysfunction is linked to cognitive impairment.
  • Thyroid stimulating hormone is a standard dementia screening test.
  • Emerging evidence suggests a connection between thyroid disorders and Alzheimer's disease.

Purpose of the Study:

  • To review the role of thyroid hormone in central nervous system development and function.
  • To summarize research associating thyroid function with dementia risk.
  • To explore biological mechanisms underlying the thyroid-dementia link.

Main Methods:

  • Literature review of population-based studies.
  • Analysis of research on thyroid hormone's CNS effects.
  • Exploration of proposed biological pathways.

Main Results:

  • Thyroid hormone is vital for normal brain development and regulation.
  • Studies indicate associations between hypothyroidism/hyperthyroidism and Alzheimer's disease.
  • Potential mechanisms involve amyloid processing, neurodegeneration, and vascular factors.

Conclusions:

  • Thyroid function is a significant factor in cognitive health.
  • Further research into thyroid hormone's impact on Alzheimer's disease pathogenesis is warranted.
  • Thyroid-mediated pathways may represent novel therapeutic targets.